Evidence map›Paper›PMID 38790929›Full record

ArticleBiomedicines2024

Relationship of Hematological Profiles with the Serum Complement System in Patients with Systemic Lupus Erythematosus.

Yolanda Fernández-Cladera, María García-González, Marta Hernández-Díaz, Fuensanta Gómez-Bernal, Juan C Quevedo-Abeledo, Agustín F González-Rivero, Antonia de Vera-González, Cristina Gómez-Moreno, Miguel Á González-Gay, Iván Ferraz-Amaro

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yolanda Fernández-CladeraDivision of Central Laboratory, Hospital Universitario de Canarias, 38320 Tenerife, Spain.
María García-GonzálezDivision of Rheumatology, Hospital Universitario de Canarias, 38320 Tenerife, Spain.ORCID 0000-0001-7600-5308
Marta Hernández-DíazDivision of Rheumatology, Hospital Universitario de Canarias, 38320 Tenerife, Spain.
Fuensanta Gómez-BernalDivision of Central Laboratory, Hospital Universitario de Canarias, 38320 Tenerife, Spain.ORCID 0000-0002-8597-1943
Juan C Quevedo-AbeledoDivision of Rheumatology, Hospital Doctor Negrín, 35010 Las Palmas de Gran Canaria, Spain.
Agustín F González-RiveroDivision of Central Laboratory, Hospital Universitario de Canarias, 38320 Tenerife, Spain.ORCID 0000-0002-9712-6990
Antonia de Vera-GonzálezDivision of Central Laboratory, Hospital Universitario de Canarias, 38320 Tenerife, Spain.
Cristina Gómez-MorenoSchool of Nursing, Fundación Jiménez Díaz, Autonomous University of Madrid, 28040 Madrid, Spain.
Miguel Á González-GayDivision of Rheumatology, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, 28040 Madrid, Spain.ORCID 0000-0002-7924-7406
Iván Ferraz-AmaroDivision of Rheumatology, Hospital Universitario de Canarias, 38320 Tenerife, Spain.ORCID 0000-0003-0197-5267

Funding

Instituto de Salud Carlos III PI20/00084
6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder identified by hematological abnormalities including anemia, leukopenia, and thrombocytopenia. Complement system disturbance is implicated in the pathogenesis of SLE. In this work, we aim to study how a full assessment of the complement system, which includes the evaluation of its three pathways, relates to blood cell counts in a population of patients with SLE. New-generation functional assays of the classical, alternative, and lectin pathways of the complement system were conducted in 284 patients with SLE. Additionally, serum levels of inactive molecules (C1q, C2, C3, C4, factor D) and activated molecules (C3a), as well as regulators (C1-inhibitor and factor H), were evaluated. Complete blood cell counts were analyzed. Multivariable linear regression analysis was performed to study the relationship of hematological profiles with this full characterization of the complement system. After multivariable adjustments that included age, sex, SLICC-DI (damage), and SLEDAI (activity) scores, as well as the use of aspirin, prednisone, methotrexate, azathioprine, and mycophenolate mofetil, several relationships were observed between the C pathways and the individual products and blood cells profile. Lower values of C1q and C2 were associated with lower hemoglobin levels. Lower leukocyte counts showed significantly lower values of C4, C1 inhibitor, C3, factor D, and alternative pathway functional levels. Neutrophil counts showed significant negative relationships only with the alternative pathway and C1-inh. In the case of lymphocytes, associations were found, especially with functional tests of the classical and alternative pathways, as well as with C2, C4, C3, and C3a. On the contrary, for platelets, significance was only observed, after multivariable adjustment, with lower C2 concentrations. In conclusion, the serum complement system and hematological profile in SLE are independently linked, after adjustment for disease activity and damage. These relationships are basically negative and are predominantly found in lymphocytes.

Indexed as

blood cells countcomplement systemhemoglobinleucocyteslymphocytesmonocytesneutrophilsplateletssystemic lupus erythematosus

Identifiers

PMID38790929
PMCPMC11117834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.